Novel water-soluble and highly efficient dual type I/II next generation inhibitors of FMS-like tyrosine kinase 3...

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• FMS-like tyrosine kinase (FLT3) mutations are common in acute myeloid leukemia (AML), correlating with poor prognosis.
• Existing FLT3 inhibitors often lack selectivity or face resistance, limiting their therapeutic effectiveness.
• Marbotinib, a tyrosine kinase inhibitor, has shown promise, but water-soluble derivatives are needed for improved bioavailability.

Purpose of the Study:

• To develop novel, water-soluble Marbotinib derivatives with enhanced selectivity and efficacy against FLT3 mutations.
• To investigate the potential of these derivatives in overcoming resistance mechanisms in AML.
• To evaluate the in vivo performance of these compounds compared to current standard treatments.

Main Methods:

• Design and synthesis of water-soluble Marbotinib derivatives, including bisarylmethanone-based compound 29 and carbamate derivative 42.
• In vitro biological testing to assess inhibition of FLT3-ITD and FLT3-TKD mutations.
• Molecular modeling to guide the attachment of amine functions for improved binding and solubility.
• Salt formation and in vivo studies to evaluate efficacy and bioavailability.

Main Results:

• Compounds 29 and 42 demonstrated potent inhibition of both FLT3-ITD and FLT3-TKD mutations.
• The synthesized derivatives exhibited good water solubility and enhanced biological availability.
• In vivo studies showed promising results, with notable improvements over midostaurin, Quizartinib, and Marbotinib derivatives.

Conclusions:

• Water-soluble Marbotinib derivatives represent a promising new class of highly selective FLT3 inhibitors for AML treatment.
• These compounds effectively target key FLT3 mutations and demonstrate superior in vivo efficacy.
• Further development of these derivatives could lead to improved therapeutic options for AML patients with FLT3 mutations.